Loading...
•
Dec 31, 2020
Halozyme Q4 2020 Earnings Report
Reported fourth quarter revenue of $121.7 million and earnings per share of $0.50.
Key Takeaways
Halozyme reported a successful fourth quarter, driven by the launch of DARZALEX® SC with ENHANZE®. The company transitioned to a profitable, high-growth company with strong prospects for continued growth.
Fourth quarter revenue was $121.7 million, compared to $53.7 million for the fourth quarter of 2019.
Earnings per share for the fourth quarter was $0.50, compared to a net loss in the fourth quarter of 2019 of $0.24 per share.
Operating income for the fourth quarter was $77.6 million, compared to an operating loss of $32.1 million in the fourth quarter of 2019.
Royalties increased by 86% compared to the prior year period, driven by the strong DARZALEX FASPRO® launch.
Halozyme
Halozyme
Halozyme Revenue by Segment
Revenue by Segment
Royalties Revenue
CapyFin.comUnder Collaborative Agreements Revenue
CapyFin.com Forward Guidance
Halozyme expects revenues of $375 million to $395 million, representing year-over-year growth of 40%-48%, with revenues from royalties projected to approximately double versus 2020; Operating Income of $215 million to $235 million, representing year-over-year growth of 49%-63%; Earnings per share on a GAAP basis of $1.40 to $1.55, representing year-over-year growth of 54%-70%.
Positive Outlook
- Revenues of $375 million to $395 million, representing year-over-year growth of 40%-48%
- Revenues from royalties projected to approximately double versus 2020
- Operating Income of $215 million to $235 million, representing year-over-year growth of 49%-63%
- Earnings per share on a GAAP basis of $1.40 to $1.55, representing year-over-year growth of 54%-70%
- The Company plans to repurchase up to $125 million in common stock during 2021 as part of the $550 million three-year share repurchase plan authorized by Halozyme’s board of directors in 2019.
Revenue & Expenses
Visualization of income flow from segment revenue to net income